Raltegravir

CHEMBL254316 Phase 4 Aprobado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
444.4 g/mol
LogP
1.1
Phase
4

An antiretroviral medication belonging to the integrase inhibitor class, used as part of combination therapy to treat HIV infection by preventing the virus from inserting its genetic material into human cells. It is effective against HIV strains resistant to other drug classes.

Peso molecular

444,4000 g/mol

LogP

1,10

TPSA

150,00 Ų

Regla de cinco de Lipinski

Cumple

Áreas terapéuticas

Mecanismo de acción

Inhibits viral integrase, preventing the insertion of viral DNA into the host cell genome and blocking viral replication.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Inhibits viral integrase, preventing the insertion of viral DNA into the host cell genome and blocking viral replication.

Estructura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2C)o1

InChI

InChI=1S/C20H21FN6O5/c1-10-25-26-17(32-10)16(30)24-20(2,3)19-23-13(14(28)18(31)27(19)4)15(29)22-9-11-5-7-12(21)8-6-11/h5-8,28H,9H2,1-4H3,(H,22,29)(H,24,30)

Molecular Formula

C20H21FN6O5

HBD / HBA

3 / 9

Enlaces Rotables

6

Átomos Pesados

32

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

An antiretroviral medication belonging to the integrase inhibitor class, used as part of combination therapy to treat HIV infection by preventing the virus from inserting its genetic material into human cells. It is effective against HIV strains resistant to other drug classes.

Inhibits viral integrase, preventing the insertion of viral DNA into the host cell genome and blocking viral replication.

Yes, Raltegravir is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL254316. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 54671008. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.